Pentoxifylline, a phosphodiesterase inhibitor and non-specific TNF-α pathway antagonist, has been shown to promote a reduction in serum Alanine Aminotransferase (ALT) levels and improvement of the histological features of NASH in adult patients [12,39]. Here, TNF is linked to metabolic dysfunction-associated steatohepatitis.